A pharmaceutical combination comprising (i) a MET inhibitor and (ii) an FGFR inhibitor, or a pharmaceutically acceptable salt of the aforementioned compounds, respectively, or a prodrug thereof, respectively, and at least one pharmaceutically acceptable carrier. A pharmaceutical combination according to claim 1 for the simultaneous, separate or sequential use of components (i) and (ii). The pharmaceutical combination according to claim 1 in the form of a fixed combination. The pharmaceutical combination according to claim 1 in the form of a dosage form or a combination kit for combined administration wherein the FGFR tyrosine kinase inhibitor and the MTE tyrosine kinase inhibitor can be administered independently of each other simultaneously or separately during the time intervals, When these time intervals allow the components of the compound to manifest joint activity. A pharmaceutical combination according to any one of 1-4, wherein the MTE tyrosine kinase inhibitor is selected from the group consisting of (E) -2- (1- (3 - ((7-fluoroquinolin-6-yl) methyl) imidazo [1,2-b] pyridazin-6- yl) ethylidene) hydrazinecarboxamide and 2-fluoro-N-methyl-4 - [(7-quinolin-6-ylmethyl) imidazo [1,2-b] triazin-2-yl] benzamide, or a pharmaceutically acceptable salt or prodrug forms of these compounds, and the FGR-R tyrosine kinase inhibitor is 3- (2,6-dichloro-3,5-dimethoxy-phenyl) -1- {6- [4- (4-ethylpiperazin-1-yl) -phenylamino] -pyrimidin-4-yl} -1-methyl-urea, or a pharmaceutically acceptable salt or prodrugform of said compound. A pharmaceutical combination according to any one of 1-4 containing an additional agent, or a pharmaceutically acceptable salt or prodrug thereof. A pharmaceutical combination according to any one of 1-4, containing an amount that is c1. Фармацевтическая комбинация, содержащая (i) ингибитор MET и (ii) ингибитор FGFR, либо фармацевтически приемлемую соль вышеуказанных соединений, соответственно, либо их пролекарственную форму, соответственно, и, по край
